Promising Outlook for DBV Technologies SA: Accelerated BLA Submission and Revenue Growth Potential

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on DBV Technologies SA – American (DBVT – Research Report). The associated price target remains the same with $10.00.

Jonathan Wolleben has given his Buy rating due to a combination of factors surrounding DBV Technologies SA – American’s recent developments and future prospects. The FDA’s agreement that the ongoing Phase 3 VITESSE trial in 4-7 year olds provides a sufficient safety database for a BLA submission is a significant milestone. This decision allows DBVT to forego the planned COMFORT Children safety study, thereby accelerating the BLA submission timeline to the first half of 2026 and conserving cash resources.
Furthermore, the anticipated data from the VITESSE trial, expected in the fourth quarter of 2025, is a critical catalyst for the company’s shares and a pivotal step towards approval. The company’s financial strategy also involves a differentiated pricing model for different age groups, which is expected to enhance revenue potential. With a projected launch in mid-2027 for the 4-7 year olds and a high probability of success, Wolleben sees a promising outlook for DBVT, estimating combined peak sales to exceed $2 billion.